Publications

1 2 3 4 5 6 7 8 12 23 33 44

Nicholas J Vogelzang, Tomasz M Beer, Winald Gerritsen, Stéphane Oudard, Pawel Wiechno, Bozena Kukielka-Budny, Vladimir Samal, Jaroslav Hajek, Susan Feyerabend, Vincent Khoo, Arnulf Stenzl, Tibor Csöszi, Zoran Filipovic, Frederico Goncalves, Alexander Prokhorov, Eric Cheung , Arif Hussain, Nuno Sousa, Amit Bahl, Syed Hussain, Harald Fricke, Pavla Kadlecova, Tomas Scheiner, Roman P Korolkiewicz, Jirina Bartunkova, Radek Spisek, VIABLE Investigators.

Efficacy and Safety of Autologous Dendritic Cell-Based Immunotherapy, Docetaxel, and Prednisone vs Placebo in Patients With Metastatic Castration-Resistant Prostate Cancer: The VIABLE Phase 3 Randomized Clinical Trial

JAMA Oncol. 2022 Feb 10;e217298. doi: 10.1001/jamaoncol.2021.7298. Online ahead of print.

Lukas Rob, David Cibula, Pawel Knapp, Peter Mallmann, Jaroslav Klat, Lubos Minar, Pavel Bartos, Josef Chovanec, Petr Valha, Marek Pluta, Zdenek Novotny, Jiri Spacek, Bohuslav Melichar, Dariusz Kieszko, Jitka Fucikova, Tereza Hrnciarova, Roman Pawel Korolkiewicz, Marek Hraska, Jirina Bartunkova, Radek Spisek.

Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial

J Immunother Cancer. 2022 Jan;10(1):e003190. doi: 10.1136/jitc-2021-003190.

Jitka Fucikova, An Coosemans, Sandra Orsulic, David Cibula, Ignace Vergote, Lorenzo Galluzzi, Radek Spisek.

Immunological configuration of ovarian carcinoma: features and impact on disease outcome

J Immunother Cancer. 2021 Oct;9(10):e002873. doi: 10.1136/jitc-2021-002873.